t(11;14)(q13;q32). (4) The expression of cyclin D1 is a common event in MM (18/52, 35%). In order to assess the presence of t(11;14), FISH studies were done on five MM patients expressing cyclin D1, according to Avet-Loiseau et al. 6 In three out of five cases, we detected a t(11;14)(q13;q32) and, in the two others, extra copies of chromosome 11. Five MM patients with no cyclin D1 expression were also analyzed by FISH, we did not detect any chromosome 11 abnormalities. The prognostic value of cyclin D1 in MM remains to be evaluated.
Although, cyclin D2 and cyclin D3 mRNAs were ubiquitously expressed, in contrast with cyclin D2 protein, cyclin D3 protein was never present except in HCL. These findings indicate that some regulatory mechanisms still persist in tumor cells at a post-transcriptional level. In agreement with the study of Suzuki et al, 2 there is a selective expression of cyclin D in lymphoproliferative disorders, the significance of such phenomenon has to be studied. The finding of Ph chromosome in children suffering from ALL is closely associated with older age at presentation, a high leukocyte count, and high incidence of central nervous system leukemia. 1 The presence of BCR/ABL fusion in leukemic cells usually indicates highrisk leukemia warranting hemopoietic stem cell transplantation.
We report a new case of Ph+ ALL with two fusion BCR/ABL signals determined by FISH. The cytogenetic findings of additional chromosomal changes were precisely specified by using FISH, M-FISH and CGH methods.
A 5-year-old female presented with a 2-week history of hematoma, petechiae and epistaxis. Physical examination was remarkable for ecchymoses and scattered petechiae, but no lymphadenopathy or hepatomegaly. Initial laboratory results showed hemoglobin 104 g/l,
Figure 1
G-banded karyotype 46,XX,der(4),der(7),t(9;22)(q34;q11). The derivative chromosomes and translocation are indicated by arrows.
Figure 2
Dual-colour FISH on nuclei and metaphase chromosomes with ES BCR/ABL probe (Vysis, Downers Grove, IL, USA). Positive BCR/ABL fusion signals are indicated by arrows.
Figure 3
FISH with painting probes for chromosome 4 (SpectrumOrange, Vysis) and chromosome 13 (FITC, Vysis) confirmed translocation t(4;13). The space between green and red signals indicates the chromosomal insertion.
Figure 4
FISH with painting probe for chromosome 2 (Spectrum Orange, Vysis) showed insertion into the long arm of chromosome der(4). white blood cells 6.8 × 10 9 /l (36% blasts) and platelet count 68 × 10 9 /l. The cerebrospinal fluid was negative for leukemic cells. Abdominal ultrasound was normal except for borderline splenomegaly (8.0 cm). Bone marrow aspirate and biopsy revealed 94.8% blasts that were consistent with L2 morphology. Immunophenotyping showed results suggestive of pre-B ALL with iIgM (62%) and iTdT (86%) and with aberrant expression of CD66c (77%). Using molecular techniques the m-BCR/ABL fusion gene was confirmed. Because of the presence of Ph chromosome the patient was enrolled on the high risk ALL-BFM 95 protocol for B-precursor ALL and begun on fourdrug induction with prednisone, vincristine, daunorubicin and L-asparaginase. At day 8 she had no evidence of peripheral blast cells, at day 15 bone marrow showed reduction of lymphoblasts to 8%. She tolerated induction chemotherapy well and currently continues her treatment 3 weeks from diagnosis.
The cytogenetic examination from bone marrow cells has shown normal karyotype 46, XX in four mitoses and abnormal clone with 46, XX, der(4), der(7), t(9;22)(q34;q12) in 22 mitoses 2 ( Figure 1 ). Using BCR/ABL ES probe (cut-off level 0%, Vysis) we evaluated 500 interphase cells and two abnormal clones were detected: the first one with one fusion signal BCR/ABL gene in 50% of interphase cells and the second one two fusion signals, the typical picture of double Ph chromosome (Figure 2 ), in 37% of examined cells. At evaluation of these two fusions on metaphases, we found one of these fusions located on chromosome 22 and the second one on chromosome 9 (Figure 2 ).
Figure 5
CGH average ratio profile. The vertical bars indicate regions with deletion (red) of chromosome 7q and gains on chromosomes 1, 2 and 13 (green).
Using RT-PCR from RNA isolated from bone marrow cells at the time of diagnosis the breakpoint in minor e1/a2 region of BCR gene was found.
M-FISH method was used to determine complex karyotype. By this method derivative chromosome 7 as the result of translocation t(1;7) and derivative chromosome 4 as the result of t(4;13?) were identified by M-FISH. Because of the poor quality of mitoses and bad morphology of chromosomes the result of M-FISH had to be verified by the FISH method with painting probes for chromosomes 4 and 13. The change der(4)t(4;13) has been verified although a small region between these two chromosomes did not hybridize with these probes (Figure 3) . Because the amplification of chromosome 2q was identified by CGH, we used painting probe for chromosome 2 and detected a very small insertion into derivative chromosome 4 ( Figure 4) . The insertion was situated between genetic material of chromosomes 4 and 13. This insertion was too small to be seen in M-FISH karyotype. Without using CGH this change would easily escape identification.
When the CGH method 3 was added to complete cytogenetic, FISH and M-FISH results we found amplification of chromosomes 1q, 2q, 13q and loss of 7q ( Figure 5 ).
The finding of double fusion signals on chromosomes 22 and 9 in one abnormal clone is unusual and has not been described in childhood ALL previously. Hsu et al 4 described one ABL/BCR fusion on chromosome 9 in a Ph-negative CML case and Reddy and Grove 5 recognized fusion signals on chromosomes 22 and 9 and evaluated the finding as either a cryptic reciprocal exchange between BCR and ABL loci or as the reversal of a Philadelphia translocation in a CML patient.
In our case, we speculate about amplification of BCR/ABL in one abnormal clone followed by reciprocal exchange between chromosomes 9 and 22. Our speculation is backed by findings of further amplification on chromosomes 1, 2 and 13 of this patient.
Ph translocation was followed by additional changes resulting in complex karyotype. The additional chromosomal changes in more than half of patients mostly appear to have no prognostic or clinical impact except for monosomy 7, which is accompanied with an adverse outcome. We have found an additional change involving chromosome 7 as the deletion and translocation with amplified material of chromosome 1. This additional unbalanced translocation with further copies of 1q occurs in 16% of children with ALL. The second unbalanced change includes chromosomes 4, 13 and 2, and is a new chromosome change observed in childhood ALL. Without using CGH we could not have determined amplification of chromosome 1q, 2q and 13q and deletion of 7q masked by translocation.
In conclusion, we report clinical, cytogenetic, FISH, M-FISH and
Leukemia CGH results in a child with ALL. The cytogenetic finding of Ph chromosome was confirmed by the FISH method, which showed double fusion signals, one on chromosome 22 and the second on chromosome 9. To our knowledge, this case is the first published finding of two fusion signals in Ph+ ALL. Using other molecular cytogenetic methods complex karyotype of patient was precisely determined as: 46,XX,der(4)ins(4;2)(q34;q32q33)t(4;13)(q34;q14),der(7)del(7)(q32qter) t(1;7)(q22;q32), t(9;22)(q34;q11). The results also validate the necessity of utilization of all methods of cytogenetics, molecular cytogenetics and molecular genetics for precise determination of chromosomal changes. 
Cytogenetic and FISH analyses in five patients with hypoplastic bone marrow

TO THE EDITOR
The differential diagnosis between 'true' SAA and hypoplastic MDS is often difficult because of a reduced bone marrow cellularity.
1,2 Fundamental discriminant clues can be provided by trephine biopsy and by the identification of a chromosome aberration, 3 that, however, has been reported in SAA patients too.
We report on five patients, aged 20-59 years, observed at our Institution between March 1989 and August 1995. Their main clinicohematological characteristics are listed in Table 1 . Cytogenetics and FISH results are reported in Table 2 . At diagnosis an initial cytogenetic analysis showed a normal chromosome pattern in all the patients. All of them evolved into AML showing clonal karyotype defects described according to ISCN 4 (trisomies and monosomies were considered clonal when present in at least two and three metaphases, respectively). We decided to employ FISH retrospectively in order to establish if any minor subclone, carrying the chromosome abnormality detected by cytogenetics at the time of AML transformation, was already present at diagnosis. In order to reinforce the interphase FISH analysis of small subpopulations of cells we decided to apply the probe discovering the clonal chromosome defect along with an additional probe used as an internal control (dual-color FISH). All probes were commercially obtained (Oncor, Gaithersburg, MD, USA).
The digoxygenated 5q31 DNA probe was applied to metaphase cells only along with the 5␣ probe. Its cut-off value was obtained by screening 1000 mitoses from 10 normal controls. We determined the one-sided 95% confidence limit using a binomial distribution for the proportion of metaphase cells that were normal or that carried the del(5)(q13q31). We detected the probability of discovering 0, 1, 2, 3 cells with del(5)(q13q31) by using the upper boundary of the 95% confidence interval. 5 As in normal subjects, 3 was the highest number of cells lacking the 5q31DNA probe signal, probably because of a hybridization failure, the normal range for the cells with this karyotypic defect was fixed at 0.8%.
Monosomy 7 or trisomy 8 or other numerical defects were considered clonal by metaphase and interphase FISH when the percentages of the cells with such abnormalities were above the cut-off value determined for each numerical change. The cut-off value was obtained by screening 25 mitoses and 200 interphase cells from 10 normal controls. Monosomy 7 cut-off was determined by applying the 7␣ probe together with a 12␣ probe. We calculated the mean percentage of mitoses or cells showing two spots due to the internal control and only one spot due to the 7␣ probe plus three times the standard deviation. Monosomy 7 cut-off value for metaphase FISH was 8%; that for interphase FISH was 5%. Trisomy 4 and 8 cut-offs were obtained in the same way and were fixed at 0% for both the numerical defects when considering mitoses, at 2.3% and at 2.5%, respectively, when examining interphase cells.
Despite the high interphase FISH cut-offs for monosomies and trisomies making the identification of minor subclones marked by such abnormalities difficult, this technique succeeded in demonstrating that the clonal defect was already present at disease onset in a few interphase cells obtained from four of our patients (Nos 1, 2, 4 and 5). This result was confirmed by metaphase FISH, that detected similar percentages of clonogenic cells in the same patients, suggesting that, initially, the chromosome defect was really present in a small subpop- ulation of cells. Moreover, a careful review of the karyotypes, obtained at disease onset and considered normal on an initial conventional cytogenetics investigation, demonstrated that few mitoses of the same four patients carried the clonal abnormalities observed on leukemic transformation and retrospectively identified by FISH. These cytogenetics and FISH results might be explained by the very small size of the abnormal clone and not by the low mitotic rate with poor quality metaphases often observed in patients with hypoplastic marrows. In both situations, however, FISH plays an important role in identifying clonogenic cells that may easily escape cytogenetic detection.
An intriguing point in patients with hypocellular marrow is the differential diagnosis between 'true' SAA and hypoplastic MDS. [1] [2] [3] In our patients FISH alone was unable to discriminate between true SAA and hypoplastic MDS, as the presence of a chromosome abnormality per se does not help to make a discriminatory diagnosis. However, karyotypic defects such as monosomy 7, trisomy 8 and sporadically trisomy 6 have been observed in SAA evolving into MDS or into AML. 3 Therefore, an overlap between SAA and MDS may actually exist. 2 This possibility is further illustrated by our patient No. 5, who showed an abnormality identifying a particular subgroup of MDS with a very low probability of evolving into AML, ie a del(5)(q13q31), accompanied by an increased marrow reticulin on trephine biopsy, a sign predictive of AML evolution. 1 This case initially classified as hypo-MDS ultimately developed into AML-M4 88 months after initial diagnosis.
In conclusion, the present FISH study was made possible by conventional cytogenetics, the only reason that the abnormalities present in each case were known. Cytogenetics and FISH were complementary; the latter succeeded in discovering minor subclones at diagnosis and, demonstrating their expansion, it was able to predict AML transformation.
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